In the training cohort, the male gender, European Treatment and Outcome Study for CML(EUTOS)Long-Term Survival(ELTS)intermediate-risk, ELTS high-risk, high WBC(≥130×109/L or 120×109/L, MMR or MR4)and low HGB(<110 g/L)at diagnosis were significantly related with poor molecular responses and were given points based on their regression coefficients. The gene discussed is CYGB; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.